ML-336 |
Catalog No.GC11348 |
ML-336은 VEEV(Venezuelan equine encephalitis virus) 비구조 단백질 2를 표적으로 하여 바이러스 RNA의 전사와 복제를 억제한다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1613465-33-0
Sample solution is provided at 25 µL, 10mM.
IC50: 32, 20, and 41 nM for TC-83, V3526, and Trinidad donkey strains, respectively.
ML-336 is an inhibitor for VEEV-induced cytopathic effect.
Alphaviruses like Venezuelan Equine Encephalitis Virus (VEEV) are positive-sense, enveloped, single stranded RNA viruses that are widely geographically distributed. VEEVs are found to be arthropod-borne viruses that are known to cause arthritis, encephalitis, rash, as well as death in humans.
In vitro: ML336 was identified as a first-in-class probe that inhibited a VEEV-induced cytopathic effect in three strains of the virus, which were V3526, TC-83, and Trinidad donkey, in the low nanomolar range without having cytotoxicity (> 50 μM, selectivity index > 1500). In addition, ML336 could reduce viral titer (more than 7.2 log) dramatically below a 1 μM drug concentration. Furthermore, ML336 showed a favorable in vitro PK profile that included moderate blood-brain barrier permeability. More importantly, ML336 seemed to be able to target the VEEV [1].
In vivo: Currently, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Chung D et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV). Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2012 Dec 17.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *